The Federal Institute for Drugs and Medical Devices (BfArM) in Germany has issued a Direct Healthcare Professional Communication (DHPC) concerning Melphalan AqVida RTD 90 mg/ml. This new formulation is a concentrate for solution for infusion with a concentration of 90 mg/ml, significantly higher than the 5 mg/ml concentration of Alkeran and other standard melphalan formulations. The 18-fold increase in concentration presents a potential risk of overdose for patients.

Healthcare providers administering melphalan hydrochloride must be aware of this higher concentration and implement appropriate measures to prevent medication errors and patient overdose. This includes careful verification of dosage calculations and administration protocols. The communication highlights the critical need for vigilance when transitioning to or using this new product to ensure patient safety.